肝细胞癌局部区域与全身治疗的进展
综述肝细胞癌局部区域与全身治疗进展,重点为免疫检查点抑制剂联合方案使不可切除患者中位生存超过2年、部分长期生存超5年;辅助免疫治疗未改善无复发生存,两项试验显示联合经动脉化疗栓塞改善无进展生存但总生存数据尚不成熟。
要点
- 免疫检查点抑制剂联合方案使不可切除肝细胞癌中位生存超过2年,部分患者长期生存超过5年。
- 辅助免疫检查点抑制剂治疗未显示改善无复发生存。
- 两项试验显示免疫检查点抑制剂联合经动脉化疗栓塞改善无进展生存,总生存数据尚不成熟。
核心结论
- 免疫检查点抑制剂联合方案显著改善不可切除肝细胞癌总生存,中位生存超过2年,部分患者长期生存超过5年。
- 辅助免疫检查点抑制剂治疗未显示改善无复发生存。
- 两项试验显示免疫检查点抑制剂联合经动脉化疗栓塞改善无进展生存,但总生存数据尚不成熟。
- 局部肝内肝细胞癌患者全身治疗的选择、序贯或联合方式及显著缓解后是否肝移植等问题常需多学科个体化决策。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 免疫检查点抑制剂联合方案使不可切除肝细胞癌中位生存超过2年,部分患者长期生存超过5年。
- 近期数据未能证明辅助免疫检查点抑制剂治疗改善无复发生存。
- 两项试验显示免疫检查点抑制剂联合经动脉化疗栓塞改善无进展生存,但总生存数据尚不成熟。
临床怎么用
- 原文未据此给出推荐;作者认为局部肝内肝细胞癌患者是否接受全身治疗、如何序贯或联合其他治疗及显著缓解后是否肝移植等问题常需多学科个体化决策,考虑肿瘤负荷、肝功能障碍程度、体能状态和患者长期治疗目标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Significant advances have occurred in the locoregional and systemic therapy landscape for hepatocellular carcinoma (HCC), with the most notable being the introduction of immune checkpoint inhibitor (ICI) combinations. ICI combinations have significantly improved the overall survival of patients with unresectable HCC, affording median survival over 2 years and long-term survival exceeding 5 years in a subset of patients. Accordingly, there has been increased interest in the earlier application of systemic therapies, including (neo)adjuvant therapy in the perioperative setting or in combination with intra-arterial therapies. However, recent data failed to demonstrate improved recurrence-free survival with use of adjuvant ICI therapy. Conversely, 2 trials showed improved progression-free survival when ICI therapies were combined with transarterial chemoembolization, although data regarding the impact on overall survival are still immature. These improved outcomes raise several new questions, including which patients with liver-localized HCC should receive systemic therapy, how should this be sequenced or combined with other available therapies, and how to manage those patients with marked responses, including consideration of liver transplantation. These questions are often determined on a case-by-case basis and best made in a multidisciplinary manner considering several factors, including tumor burden, degree of liver dysfunction, performance status, and patient's long-term goals of care.
引用
- Singal AG, Salem R, Pinato DJ, et al. Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma. Gastroenterology. 2025. PMID: 40320088. doi:10.1053/j.gastro.2025.03.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。